Skip to main content
SpringerLink
Log in
Book cover

Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma pp 39–48Cite as

Staging of Melanoma

  • Chapter
  • First Online:

  • 967 Accesses

Part of the book series: Current Clinical Pathology ((CCPATH))

Abstract

The Melanoma Staging Committee of the American Joint Committee on Cancer (AJCC) was formed in 1998 and is comprised of experts from all relevant medical specialties, including many of the major melanoma centers in North America, Europe, and Australia. This committee set up the AJCC Melanoma Staging Database for the collection of prospective outcome data on melanoma patients from 13 cancer centers and cooperative groups in order to establish and subsequently revise a melanoma staging system. The staging system for melanoma has undergone multiple revisions in the last decade, reflecting the rapid and continuous acquisition of new information and advances in this field.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000;88:1484–91.

    Article  PubMed  CAS  Google Scholar 

  2. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54:131–49.

    Article  PubMed  Google Scholar 

  3. Petro A, Schwartz J, Johnson T. Current melanoma staging. Clin Dermatol. 2004;22:223–7.

    Article  PubMed  Google Scholar 

  4. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.

    Article  PubMed  Google Scholar 

  5. Edge SE, Byrd DR, Compton CC, et al. AJCC ­cancer staging manual. New York: Springer; 2009. p. 325–40.

    Google Scholar 

  6. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902–8.

    Article  PubMed  CAS  Google Scholar 

  7. Cho YR, Chiang MP. Epidemiology, staging (new system), and prognosis of cutaneous melanoma. Clin Plast Surg. 2010;37:47–53.

    Article  PubMed  Google Scholar 

  8. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622–34.

    PubMed  CAS  Google Scholar 

  9. Balch CM, Murad TM, Soong SJ, Ingalls AL, Halpern NB, Maddox WA. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark’s and Breslow’s staging methods. Ann Surg. 1978;188:732–42.

    Article  PubMed  CAS  Google Scholar 

  10. Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, Maddox WA. The prognostic significance of ulceration of cutaneous melanoma. Cancer. 1980;45:3012–7.

    Article  PubMed  CAS  Google Scholar 

  11. Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004;11: 426–33.

    Article  PubMed  Google Scholar 

  12. Barnhill RL, Katzen J, Spatz A, Fine J, Berwick M. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol. 2005;32:268–73.

    Article  PubMed  Google Scholar 

  13. Retsas S, Henry K, Mohammed MQ, MacRae K. Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients. Eur J Cancer. 2002;38:511–6.

    Article  PubMed  CAS  Google Scholar 

  14. Scolyer RA, Thompson JF, Shaw HM, McCarthy SW. The importance of mitotic rate as a prognostic factor for localized primary cutaneous melanoma. J Cutan Pathol. 2006;33:395–6; author reply 397–399.

    Article  PubMed  Google Scholar 

  15. Gershenwald JE, Soong SJ, Balch CM, American Joint Committee on Cancer (AJCC) Melanoma Staging Committee. 2010 TNM staging system for cutaneous melanoma…and beyond. Ann Surg Oncol. 2010;17:1475–7.

    Article  PubMed  Google Scholar 

  16. Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0–4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7: 87–97.

    Article  PubMed  CAS  Google Scholar 

  17. Cascinelli N, Belli F, Santinami M, Fait V, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol. 2000;7:469–74.

    Article  PubMed  CAS  Google Scholar 

  18. Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28:2452–9.

    Article  PubMed  Google Scholar 

  19. Rao UN, Ibrahim J, Flaherty LE, Richards J, Kirkwood JM. Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol. 2002;20:2053–7.

    Article  PubMed  CAS  Google Scholar 

  20. Buzaid R. Critical analysis of the current AJCC staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol. 1997;15:1039–51.

    PubMed  CAS  Google Scholar 

  21. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008;35:433–44.

    Article  PubMed  Google Scholar 

  22. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000;18:3782–93.

    PubMed  CAS  Google Scholar 

  23. Eton O, Legha SS, Moon TE, et al. Prognostic factors for survival of patients treated systemically for ­disseminated melanoma. J Clin Oncol. 1998;16: 1103–11.

    PubMed  CAS  Google Scholar 

  24. Bedikian AY, Johnson MM, Warneke CL, et al. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest. 2008;26:624–33.

    Article  PubMed  CAS  Google Scholar 

  25. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193–201.

    PubMed  CAS  Google Scholar 

  26. Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, Durant JR. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol. 1983;1:126–34.

    PubMed  CAS  Google Scholar 

  27. Keilholz U, Martus P, Punt CJ, et al. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer. 2002;38:1501–11.

    Article  PubMed  CAS  Google Scholar 

  28. Franzke A, Probst-Kepper M, Buer J, et al. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer. 1998;78:40–5.

    Article  PubMed  CAS  Google Scholar 

  29. Deichmann M, Benner A, Bock M, et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol. 1999;17:1891–6.

    PubMed  CAS  Google Scholar 

  30. Brand CU, Ellwanger U, Stroebel W, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer. 1997;79:2345–53.

    Article  PubMed  CAS  Google Scholar 

  31. Das Gupta T, Bowden L, Berg JW. Malignant melanoma of unknown primary origin. Surg Gynecol Obstet. 1963;117:341–5.

    CAS  Google Scholar 

  32. Giuliano AE, Moseley HS, Morton DL. Clinical aspects of unknown primary melanoma. Ann Surg. 1980;191:98–104.

    Article  PubMed  CAS  Google Scholar 

  33. Cormier JN, Xing Y, Feng L, et al. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer. 2006;106:2012–20.

    Article  PubMed  Google Scholar 

  34. Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol. 2008;26:535–41.

    Article  PubMed  Google Scholar 

  35. Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol. 1992;8: 400–14.

    Article  PubMed  CAS  Google Scholar 

  36. Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol. 2000;7:160–5.

    Article  PubMed  CAS  Google Scholar 

  37. Bevilacqua RG, Coit DG, Rogatko A, Younes RN, Brennan MF. Axillary dissection in melanoma. Prognostic variables in node-positive patients. Ann Surg. 1990;212:125–31.

    Article  PubMed  CAS  Google Scholar 

  38. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg. 1991;214:491–9. discussion 499–501.

    Article  PubMed  CAS  Google Scholar 

  39. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976–83.

    PubMed  CAS  Google Scholar 

  40. Day CL, Day Jr CL, Harrist TJ, Gorstein F, et al. Malignant melanoma. Prognostic significance of “microscopic satellites” in the reticular dermis and subcutaneous fat. Ann Surg. 1981;194:108–12.

    Article  PubMed  Google Scholar 

  41. Mohr P, Eggermont AM, Hauschild A, Buzaid A. Staging of cutaneous melanoma. Ann Oncol. 2009;20(Suppl 6):vi14–21.

    Article  PubMed  Google Scholar 

  42. Balch CM, Soong SJ. Predicting outcomes in metastatic melanoma. J Clin Oncol. 2008;26:168–9.

    Article  PubMed  Google Scholar 

  43. Haass NK, Smalley KS. Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy. Mol Diagn Ther. 2009;13: 283–96.

    PubMed  CAS  Google Scholar 

  44. Bogunovic D, O’Neill DW, Belitskaya-Levy I, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA. 2009;106: 20429–34.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Hartford Hospital, Hartford, CT, USA

    Zendee Elaba M.D.

  2. Department of Dermatology, University of Connecticut Health Center, Farmington, CT, USA

    Michael J. Murphy M.D., Philip Kerr M.D. & Jane M. Grant-Kels M.D.

Authors
  1. Zendee Elaba M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael J. Murphy M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philip Kerr M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jane M. Grant-Kels M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zendee Elaba M.D. .

Editor information

Editors and Affiliations

  1. Health Center, Department of Dermatology, University of Connecticut, Farmington, 06030, Connecticut, USA

    Michael J. Murphy

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Elaba, Z., Murphy, M.J., Kerr, P., Grant-Kels, J.M. (2012). Staging of Melanoma. In: Murphy, M. (eds) Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. Current Clinical Pathology. Springer, New York, NY. https://doi.org/10.1007/978-1-60761-433-3_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-433-3_4

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-60761-432-6

  • Online ISBN: 978-1-60761-433-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation